Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Rating of “Moderate Buy” by Brokerages

Posted by Brenda Bartman on May 29th, 2026

Shares of Edwards Lifesciences Corporation (NYSE:EW – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the twenty-eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $95.6522.

A number of analysts have recently weighed in on the stock. Mizuho set a $95.00 price target on shares of Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. UBS Group reiterated a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Evercore reiterated an “outperform” rating and issued a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday, April 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Finally, Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th.

Read Our Latest Stock Report on Edwards Lifesciences

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 620 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares in the company, valued at approximately $3,278,948.54. The trade was a 1.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 105,829 shares of company stock worth $8,799,770. Company insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Several institutional investors and hedge funds have recently bought and sold shares of EW. Norges Bank purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. Viking Global Investors LP purchased a new stake in Edwards Lifesciences in the 3rd quarter worth $238,688,000. Marshall Wace LLP increased its holdings in Edwards Lifesciences by 66.1% in the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after acquiring an additional 2,359,128 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in Edwards Lifesciences by 19.6% in the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after acquiring an additional 2,287,783 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 0.6%

NYSE:EW opened at $85.96 on Friday. Edwards Lifesciences has a fifty-two week low of $72.30 and a fifty-two week high of $88.28. The stock has a market capitalization of $49.50 billion, a P/E ratio of 45.73, a P/E/G ratio of 2.17 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The company’s 50-day simple moving average is $81.66 and its 200-day simple moving average is $82.98.

Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same period last year, the business earned $0.64 EPS. The company’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts anticipate that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

About Edwards Lifesciences

(Get Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.